These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 18565854)

  • 1. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity.
    Nishimura R; Baker J; Beilhack A; Zeiser R; Olson JA; Sega EI; Karimi M; Negrin RS
    Blood; 2008 Sep; 112(6):2563-74. PubMed ID: 18565854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells.
    Niu C; Jin H; Li M; Xu J; Xu D; Hu J; He H; Li W; Cui J
    BMC Immunol; 2015 Oct; 16():61. PubMed ID: 26458364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.
    Olson JA; Leveson-Gower DB; Gill S; Baker J; Beilhack A; Negrin RS
    Blood; 2010 May; 115(21):4293-301. PubMed ID: 20233969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production.
    Baker J; Verneris MR; Ito M; Shizuru JA; Negrin RS
    Blood; 2001 May; 97(10):2923-31. PubMed ID: 11342413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia.
    Linn YC; Hui KM
    Leuk Lymphoma; 2003 Sep; 44(9):1457-62. PubMed ID: 14565644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
    Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
    Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow mesenchymal stem cells reduce the antitumor activity of cytokine-induced killer/natural killer cells in K562 NOD/SCID mice.
    Li Y; Qu YH; Wu YF; Wang XP; Wei J; Huang WG; Zhou DH; Fang J; Huang K; Huang SL
    Ann Hematol; 2011 Aug; 90(8):873-85. PubMed ID: 21234566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells.
    Cappuzzello E; Sommaggio R; Zanovello P; Rosato A
    Cytokine Growth Factor Rev; 2017 Aug; 36():99-105. PubMed ID: 28629761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells.
    Bremm M; Pfeffermann LM; Cappel C; Katzki V; Erben S; Betz S; Quaiser A; Merker M; Bonig H; Schmidt M; Klingebiel T; Bader P; Huenecke S; Rettinger E
    Front Immunol; 2019; 10():1218. PubMed ID: 31214182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation.
    Wu X; Sharma A; Oldenburg J; Weiher H; Essler M; Skowasch D; Schmidt-Wolf IGH
    Front Immunol; 2021; 12():731767. PubMed ID: 34691037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue-specific homing and expansion of donor NK cells in allogeneic bone marrow transplantation.
    Olson JA; Zeiser R; Beilhack A; Goldman JJ; Negrin RS
    J Immunol; 2009 Sep; 183(5):3219-28. PubMed ID: 19657090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.
    Laport GG; Sheehan K; Baker J; Armstrong R; Wong RM; Lowsky R; Johnston LJ; Shizuru JA; Miklos D; Arai S; Benjamin JE; Weng WK; Negrin RS
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1679-87. PubMed ID: 21664472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
    Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
    Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
    Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures.
    Bonanno G; Iudicone P; Mariotti A; Procoli A; Pandolfi A; Fioravanti D; Corallo M; Perillo A; Scambia G; Pierelli L; Rutella S
    J Transl Med; 2010 Dec; 8():129. PubMed ID: 21138560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CIK as therapeutic agents against tumors.
    Introna M
    J Autoimmun; 2017 Dec; 85():32-44. PubMed ID: 28679475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy.
    Helms MW; Prescher JA; Cao YA; Schaffert S; Contag CH
    Cancer Immunol Immunother; 2010 Sep; 59(9):1325-34. PubMed ID: 20532883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Coculture of dendritic cell with cytokine-induced killer results in a significant increase in cytotoxic activity of CIK to tumor cells in vitro and in vivo].
    Ge W; Li CH; Zhang W; Han Q; Deng WM; Chen L; You SG; Zhao CH
    Zhonghua Xue Ye Xue Za Zhi; 2004 May; 25(5):277-80. PubMed ID: 15182535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.